Chikungunya Virus Infection Clinical Trial
Official title:
Impact of Yoga on Quality of Life in Patients With Chronic Chikungunya: A Randomized Controlled Study
The purpose of this study is to assess the benefits of a 8-week yoga program on quality of
life in patients suffering from chronic chikungunya.
Studies have already shown the effectiveness of yoga practice on various arthralgia's, on the
reduction of inflammatory reactions, on psychological disorders/sleep disorders and on
quality of life. Considering quality of life as a global experience of balance between
physical and mental wellbeing, the hypothesis was that the practice of yoga would globally
improve the quality of life of patients with chronic chikungunya.
The chikungunya virus (CHIKV) is an arbovirus passed to humans by Aedes mosquitoes. Since its
description in 1952, CHIKV has caused millions of human infections in Africa, the Indian
Ocean islands, Asia, Europe and America (1). In total, since 2013, the epidemic has affected
more than 2 million people in the Americas. In Guadeloupe, the emergence of chikungunya cases
began in 2013. CHINKV was declared an epidemic in 2014 with an estimated 20,000 infected
patients.Human infection with CHIKV is characterized by a sudden onset of severe joint pains,
high fever and rash. The infection is self-limited and acute symptoms usually disappear
within one or two weeks. However, this polyarthralgia is recurrent in 30 to 40% of infected
people and can persist for years. Chikungunya is considered chronic if the symptoms persist
after three months. The chronic stage can last from a few months to several years. Chronic
chikungunya usually manifests as joint pain and stiffness, polyarthralgia (including
rheumatoid arthritis, flare-ups of spondylitis), and other general symptoms such as
intermittent headaches, edema, and paresthesia. The consequences of chronic CHIKV can be
severe, with patients becoming maladjusted to their lifestyle, feeling weakened and
diminished. Depression and medical leaves are very frequent, with many cases of disability.
Yoga is an ancestral Indian practice aiming to connect the "body" and the "soul", the "self"
and "the other". Traditionally, it is a philosophical way of living, sometimes combined with
the practice of physical exercises. In westernized countries, Yoga is usually considered as a
physical practice or an alternative therapy, using various techniques of breathing,
relaxation and poses to release tensions and decrease pain.
Studies have already shown the effectiveness of yoga practice on various arthralgia's, on the
reduction of inflammatory reactions, on psychological disorders/sleep disorders and on
quality of life. Considering quality of life as a global experience of balance between
physical and mental wellbeing, the hypothesis was that the practice of yoga, by improving
these different aspects, would globally improve the quality of life of patients with chronic
chikungunya.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02230163 -
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
|
Phase 1/Phase 2 | |
Completed |
NCT04546724 -
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
|
Phase 3 | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Active, not recruiting |
NCT04441905 -
Phase 1 Study of SAR440894 vs Placebo
|
Phase 1 | |
Completed |
NCT02562482 -
Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
|
Phase 2 | |
Completed |
NCT03028441 -
Phase I Trial of Measles Vectored Chikungungya Vaccine
|
Phase 1 | |
Completed |
NCT03807843 -
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
|
Phase 2 | |
Completed |
NCT04909411 -
Consequences of a Maternal-fetal Chikungunya Virus Infection
|
N/A | |
Completed |
NCT04786444 -
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
|
Phase 3 | |
Completed |
NCT02553369 -
Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection
|
N/A | |
Recruiting |
NCT06106581 -
A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years
|
Phase 2 | |
Recruiting |
NCT06007183 -
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
|
Phase 3 | |
Completed |
NCT03635086 -
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
|
Phase 2 | |
Completed |
NCT02861586 -
Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT04838444 -
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
|
Phase 3 | |
Completed |
NCT03483961 -
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
|
Phase 2 | |
Recruiting |
NCT06028841 -
A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)
|
Phase 3 |